Click to Share
 

Filter News
Show All Results
News By Country
News By Tag
Parkinson S Disease Remove


June 2020
WeTuMoSuSaFrTh
321
May 2020
31302928

Public Company News

Business Press Releases

Parkinson S Disease Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By Neurolixis
The United States Patent and Trademark Office (USPTO) has issued a patent on NLX-112, a drug candidate developed by Neurolixis for treatment of human movement disorders, notably levodopa-induced dyskinesia in Parkinson's disease.
By Biotech Support Group
Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching the red cell proteome, to observe and report sub-forms of α-Synuclein in Parkinson's Disease.
By Neurolixis, Inc.
Neurolixis Inc. has been awarded funds by the US Department of Defense to test its drug candidate, NLX-112, in a preclinical model of Machado-Joseph disease (MJD), a rare and disabling inherited movement disorder.
By Neurolixis Inc.
The Neurolixis lead compound, NLX-112, is at the heart of a brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans. NLX-112, a.k.a.
By Neurolixis, Inc.
The US Food and Drug Administration (FDA) gave a positive response to Neurolixis' Investigational New Drug (IND) application for NLX-112.
By Neurolixis
Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in developing novel drug formulations.
12724868
By Fighting Parkinson's Drug Free
Howard Shifke knows a thing or two about Parkinson's disease. In his book "Fighting Parkinson's...and Winning: A memoir of my recovery from Parkinson's Disease," Shifke recounts the story of his developing Parkinson's, getting diagnosed, and his daily...

Page updated every 10 minutes
Trending
Most Viewed
Daily News


Like PRLog?
9K2K1K
Click to Share